SURMOUNT-1 obesity RCT trial
A 2022 NEJM phase 3 trial in 2,539 adults reported 15 to 20.9 percent weight loss over 72 weeks, with 85 to 91 percent losing at least 5 percent of body weight.
SourceBack to search
Weight LossMetabolic
Tirzepatide
Tirzepatide is an approved dual GIP and GLP-1 receptor agonist, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management. It carries a boxed warning for thyroid C-cell tumours and requires a prescription and medical supervision.
- Lowest cost / mg
- $0.72/mg
- at Royal Peptides
- Vendors listed
- 60
- In stock
- 191 of 195
- listings
- COA reports
- 150
Vendor listings
Compare Tirzepatide prices.
Show prices as
194 listings · Tirzepatide
In stock10mgseen 3d ago
In stock10mgseen 6d ago
In stock10mgseen 5d ago
In stock10mgseen 5d ago
In stock5mgseen 4d ago
In stock5mgseen 4d ago
Royal PeptidesLowest $/mgIn stock50mgseen 3d ago
In stock30mgseen 6d ago
In stock15mgseen 7d ago
In stock10mgseen 4d ago
In stock5mgseen 4d ago
In stock10mgseen 4d ago
In stock30mgseen 3d ago
In stock5mgseen 3d ago
In stock10mgseen 4d ago
In stock15mgseen 7d ago
In stock30mgseen 6d ago
In stock10mgseen 3d ago
In stock15mgseen 4d ago
In stock10mgseen 4d ago
Overview
What is Tirzepatide?
Tirzepatide is an approved dual GIP and GLP-1 receptor agonist, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management. It carries a boxed warning for thyroid C-cell tumours and requires a prescription and medical supervision.
- Weight Management
- Glycemic Control
- Appetite Control
- Metabolic Health
What the research reports
Reported benefits of Tirzepatide
Outcomes described across the published Tirzepatide literature and ongoing study. Read each as research context, not a promised result.
- 01
Substantial weight reduction
The SURMOUNT-1 trial reported 15 to 20.9 percent weight loss across doses of 5 to 15 mg, with 85 to 91 percent of participants losing at least 5 percent.
- 02
Dual incretin receptor action
Acts at both GIP and GLP-1 receptors, a mechanism associated with larger effects than single incretin agonists in head to head work. Reported in research settings.
- 03
Glycaemic control outcomes
Phase 3 trials reported greater HbA1c reduction than insulin glargine with less hypoglycaemia in people at raised cardiovascular risk. Reported in research settings.
- 04
Cardiovascular and kidney data
SURPASS-CVOT found non-inferiority to dulaglutide on cardiovascular outcomes, and post-hoc work reported slower kidney function decline. Reported in research settings.
- 05
Appetite and satiety change
Slowed gastric emptying and central appetite signalling reduce food intake, which is the practical driver of the weight effect. Reported in research settings.
Dosage and protocol
Tirzepatide dosage and protocol
The labelled schedule starts at 2.5 mg weekly and rises through 5, 7.5, 10 and 12.5 mg to a 15 mg maximum, increasing every four weeks to limit gastrointestinal side effects on the way.
- Route
- Subcutaneous injection
- Example range
- 2.5-15 mg
- Frequency
- Once weekly
- Timing
- Once weekly, same day, any time, with or without food.
Clinical evidence
Clinical evidence for Tirzepatide
The published record for Tirzepatide, labeled by strength so you can see what is settled and what is emerging.
SURPASS-4 phase 3 diabetes
A 2021 Lancet trial in 1,995 people at raised cardiovascular risk reported greater HbA1c reduction than insulin glargine with less hypoglycaemia over 52 weeks. Reported in the cited paper.
SourceSURPASS-CVOT outcome data
A 2025 NEJM trial in 13,165 patients with atherosclerotic disease found tirzepatide non-inferior to dulaglutide for major adverse cardiovascular events. Reported in the cited paper.
SourceInteractions
How it pairs with other peptides
- Semaglutide
- Overlapping GLP-1 agonism raises gastrointestinal side effect risk. Not combined in clinical practice.
- Insulin therapy
- Combined glucose lowering raises hypoglycaemia risk and generally requires an insulin dose reduction.
- Sulfonylureas
- Hypoglycaemia risk rises when a sulfonylurea is continued alongside incretin therapy without review.
- Oral contraceptives
- Delayed gastric emptying can affect absorption of oral medicines, which the product labelling addresses.
Questions
Frequently asked questions.
What is Tirzepatide?
Tirzepatide is a peptide compound used in research settings. It is commonly studied for its role in weight loss, metabolic, and many researchers compare supplier quality, purity, and testing data before purchasing.
What are the research benefits of Tirzepatide?
Tirzepatide is often evaluated for its potential influence on signaling pathways, recovery support, and targeted research applications. Research interest varies by peptide, formulation, and study design, so buyers typically review purity, dose, and independent lab verification before choosing a source.
How does Tirzepatide work?
Like other research peptides, Tirzepatide is typically studied for how it interacts with specific biological pathways and receptor systems. In practice, the way it is formulated, dosed, and tested matters as much as the compound itself, which is why verified suppliers and transparent COAs are important.
Is Tirzepatide for research use only?
Yes, products like Tirzepatide are generally intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying Tirzepatide?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Comparing pricing and testing records side-by-side helps reduce the risk of buying an under-tested or misrepresented product.
